Ziyuglycoside II inhibits the growth of digestive system cancer cells through multiple mechanisms
- PMID: 33941340
- DOI: 10.1016/S1875-5364(21)60033-X
Ziyuglycoside II inhibits the growth of digestive system cancer cells through multiple mechanisms
Abstract
Digestive system cancers, including liver, gastric, colon, esophageal and pancreatic cancers, are the leading cause of cancers with high morbidity and mortality, and the question of their clinical treatment is still open. Previous studies have indicated that Ziyuglycoside II (ZYG II), the major bioactive ingredient extract from Sanguisorba officinalis L., significantly inhibits the growth of various cancer cells. However, the selective anti-tumor effects of ZYG II against digestive system cancers are not systemically investigated. In this study, we reported the anti-cancer effect of ZYG II on esophageal cancer cells (OE21), cholangiocarcinoma cells (HuCCT1), gastric cancer cells (BGC-823), liver cancer cells (HepG2), human colonic cancer cells (HCT116), and pancreatic cancer cells (PANC-1). We also found that ZYG II induced cell cycle arrest, oxidative stress and mitochondrial apoptosis. Network pharmacology analysis suggested that UBC, EGFR and IKBKG are predicted targets of ZYG II. EGFR signaling was suggested as the critical pathway underlying the anti-cancer effects of ZYG II and both docking simulation and western blot analysis demonstrated that ZYG II was a potential EGFR inhibitor. Furthermore, our results showed synergistic inhibitory effects of ZYG II and chemotherapy 5-FU on the growth of cancer cells. In summary, ZYG II are effective anti-tumor agents against digestive cancers. Further systemic evaluation of the anti-cancer activities in vitro and in vivo and characterization of underlying mechanism will promote the development of novel supplementary therapeutic strategies based on ZYG II for the treatment of digestive system cancers.
Keywords: Digestive system cancers; EGFR pathway; Network pharmacology; Ziyuglycoside II.
Copyright © 2021 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Ziyuglycoside II suppressed the progression of osteosarcoma by coordinating estrogen-related receptor gamma and p53 signaling pathway.Chin J Nat Med. 2025 Mar;23(3):354-367. doi: 10.1016/S1875-5364(25)60847-8. Chin J Nat Med. 2025. PMID: 40122665
-
Ziyuglycoside II-induced apoptosis in human gastric carcinoma BGC-823 cells by regulating Bax/Bcl-2 expression and activating caspase-3 pathway.Braz J Med Biol Res. 2013 Aug;46(8):670-5. doi: 10.1590/1414-431X20133050. Epub 2013 Aug 13. Braz J Med Biol Res. 2013. PMID: 23969976 Free PMC article.
-
Ziyuglycoside II induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells.Toxicol Lett. 2014 May 16;227(1):65-73. doi: 10.1016/j.toxlet.2014.03.015. Epub 2014 Mar 28. Toxicol Lett. 2014. PMID: 24680927
-
Phytotherapeutic Activities of Sanguisorba officinalis and its Chemical Constituents: A Review.Am J Chin Med. 2018;46(2):299-318. doi: 10.1142/S0192415X18500155. Epub 2018 Feb 12. Am J Chin Med. 2018. PMID: 29433389 Review.
-
The Role of PGC-1α in Digestive System Malignant Tumours.Anticancer Agents Med Chem. 2020;20(3):276-285. doi: 10.2174/1871520619666191105125409. Anticancer Agents Med Chem. 2020. PMID: 31702508 Review.
Cited by
-
Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma.Chin Med. 2022 Jul 30;17(1):90. doi: 10.1186/s13020-022-00645-0. Chin Med. 2022. PMID: 35907976 Free PMC article. Review.
-
Identification of octyl gallate, a novel apoptosis-inducing compound for colon cancer therapy, from Sanguisorba officinalis L. by cell membrane chromatography and UHPLC-(Q)TOF-MS/MS.Heliyon. 2024 May 31;10(11):e32230. doi: 10.1016/j.heliyon.2024.e32230. eCollection 2024 Jun 15. Heliyon. 2024. PMID: 38933948 Free PMC article.
-
Effects of saponins from Chinese herbal medicines on signal transduction pathways in cancer: A review.Front Pharmacol. 2023 Mar 29;14:1159985. doi: 10.3389/fphar.2023.1159985. eCollection 2023. Front Pharmacol. 2023. PMID: 37063281 Free PMC article. Review.
-
The processed Sanguisorba officinalis L. triterpenoids prevent colon cancer through the TNF-α/NF-κB signaling pathway, combined with network pharmacology, molecular simulation dynamics and experimental verification.Front Immunol. 2025 Jun 18;16:1605326. doi: 10.3389/fimmu.2025.1605326. eCollection 2025. Front Immunol. 2025. PMID: 40607420 Free PMC article.
-
Simultaneous Determination and Pharmacokinetics Study of Three Triterpenes from Sanguisorba officinalis L. in Rats by UHPLC-MS/MS.Molecules. 2022 Aug 24;27(17):5412. doi: 10.3390/molecules27175412. Molecules. 2022. PMID: 36080179 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
